Disclosed herein are functionalized hyaluronic acid (HA), a responsive elastic polymer system comprising functionalized HA, and methods of fabrication and utilization of the same. This polymer system may be used for controlled local or systemic drug delivery release of analgesics, anesthetics, antibiotics and other drugs as well as tissue engineering articles

A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

The present technology generally relates to a biomaterial that includes a thiolated biopolymer and one or more agents that include growth factors, peptides, or combinations thereof, where the one or more agents are conjugated to the thiolated biopolymer. Also disclosed herein are wound dressings that include the biomaterial of the present technology, methods of treating a wound upon application of the wound dressing, and kits including the wound dressing and instructions for use.

A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.

Embodiments of the present disclosure provide for structures including an alloy of calcium, strontium, and magnesium.

The present disclosure relates generally to wound inserts that may include an outer layer and an inner core of biopolymers that may be used in the therapy of tunneling wounds and for facilitating wound healing. Kits for use in practicing the methods are also provided.

Low profile, self-expanding endovascular prostheses having a Ni-Ti alloy stent structure that is particularly well-suited for accessing and traversing narrow anatomical passageways and providing physiologically acceptable radial or hoop strength and longitudinal flexibility.

A ligament repair device and method is particularly suited to the demands of UCL repair using a scaffold device for surgical implantation across a torn ligament section. The implantable device includes an encapsulation of a therapeutic element for increasing cell proliferation and growth eluted through a controlled release storage element adapted to release the therapeutic agent over time as the cell growth progresses and the scaffold structure degrades or is absorbed in favor of the new cell growth for ligament repair. Reduced recovery time is afforded by the need for only an relatively small incision for implantation. The introduction of a physiologically relevant drug delivery scaffold encourages more rapid cell growth over passive, physical repairs to the connective tissue.

The present invention relates to a tissue adhesion agent having improved bio-tissue adhesiveness and bonding force by utilizing an adhesion-related gene. More specifically, a cartilage tissue adhesion composition prepared from fetal cartilage tissue-derived stem cells in which VCAN, CTGF, or EXT1 is inserted and expressed in an upregulated manner was found to show a remarkably superb adhesive force, compared to that prepared from fetal cartilage tissue-derived stem cells in which none of the genes are inserted. Accordingly, the cell composition in which the expression of VCAN, CTGF, or EXT1 is upregulated can be prepared into a tissue adhesion composition having improved bio-tissue adhesiveness and bonding force and VCAN, CTGF, or EXT1 can be provided as an additive composition for a tissue adhesion agent.